Inventor
HIRONIWA NAOKA
SG25 patents
Patents
25 patentsUS11142563B2Oct 12, 2021
Antigen-binding molecule containing modified Fc region
CHUGAI PHARMACEUTICAL CO LTD18 citations94
US10024867B2Jul 17, 2018
Ion concentration-dependent binding molecule library
CHUGAI PHARMACEUTICAL CO LTD24 citations93
US9975966B2May 22, 2018
Cytotoxicity-inducing theraputic agent
CHUGAI PHARMACEUTICAL CO LTD25 citations93
US11485790B2Nov 1, 2022
Immunoactivating antigen-binding molecule
CHUGAI PHARMACEUTICAL CO LTD6 citations85
US11168139B2Nov 9, 2021
Antigen-binding domain, and polypeptide including conveying section
CHUGAI PHARMACEUTICAL CO LTD7 citations84
US11001643B2May 11, 2021
Cytotoxicity-inducing therapeutic agent
CHUGAI PHARMACEUTICAL CO LTD9 citations84
US11154615B2Oct 26, 2021
Library of antigen-binding molecules including modified antibody variable region
CHUGAI PHARMACEUTICAL CO LTD8 citations83
US11820793B2Nov 21, 2023
Drug containing carrier into cell for forming immune complex
CHUGAI PHARMACEUTICAL CO LTD5 citations75
US11739149B2Aug 29, 2023
Antigen-binding molecule containing modified antibody variable region
CHUGAI PHARMACEUTICAL CO LTD5 citations74
US11952422B2Apr 9, 2024
Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
CHUGAI PHARMACEUTICAL CO LTD4 citations73
US11891434B2Feb 6, 2024
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CHUGAI PHARMACEUTICAL CO LTD6 citations73
US11851476B2Dec 26, 2023
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
CHUGAI PHARMACEUTICAL CO LTD5 citations73
US11400157B2Aug 2, 2022
Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
CHUGAI PHARMACEUTICAL CO LTD3 citations72
US12304960B2May 20, 2025
Anti-CD137 antigen-binding molecule and utilization thereof
CHUGAI PHARMACEUTICAL CO LTD3 citations71
US12030955B2Jul 9, 2024
Polypeptide including antigen-binding domain and carrying section
CHUGAI PHARMACEUTICAL CO LTD2 citations71
US12171830B2Dec 24, 2024
Anti-IL-31RA antibody-containing formulations
CHUGAI PHARMACEUTICAL CO LTD1 citations70
US11723976B2Aug 15, 2023
Methods of administering anti-IL31A antibody-containing formulations
CHUGAI PHARMACEUTICAL CO LTD2 citations70
US11260125B2Mar 1, 2022
Anti-IL31RA antibody-containing formulations
CHUGAI PHARMACEUTICAL CO LTD4 citations70
US12234573B2Feb 25, 2025
Library of antigen-binding molecules including modified antibody variable region
CHUGAI PHARMACEUTICAL CO LTD1 citations63
US12522648B2Jan 13, 2026
Antigen-binding molecule containing modified Fc region
CHUGAI PHARMACEUTICAL CO LTD0 citations62
US12479916B2Nov 25, 2025
Antigen-binding molecule containing modified antibody variable region
CHUGAI PHARMACEUTICAL CO LTD0 citations62
US11932697B2Mar 19, 2024
Antigen-binding domain, and polypeptide including conveying section
CHUGAI PHARMACEUTICAL CO LTD1 citations62
US12377143B2Aug 5, 2025
Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
CHUGAI PHARMACEUTICAL CO LTD0 citations61
US11243210B2Feb 8, 2022
Ion concentration-dependent binding molecule library
CHUGAI PHARMACEUTICAL CO LTD0 citations61
US12077577B2Sep 3, 2024
Polypeptide comprising aggrecan binding domain and carrying moiety
CHUGAI PHARMACEUTICAL CO LTD1 citations58